Jul 2026· Journal of Immunology· Vol 215· 0 citations
Abstract
Nanobodies have recently emerged as an alternative to classical antibodies in therapeutic and diagnostic contexts, promising improved stability and simpler manufacturing. However, many labs still rely on low throughput conventional screening methods for nanobody discovery. Here we report streamlined experimental and computational tools for discovery of nanobodies, permitting deep characterization of the binding properties of immune repertoires.
To improve nanobody discovery, we developed NanoMAP, an integrated experimental and computational pipeline for nanobody discovery. We immunized alpacas with a pool of antigens, and created a phage display library from circulating B-cells. We then panned this phage display library on each antigen separately, and used competitors or antigen variants to assess complex binding phenotypes of the immune repertoire. Finally, we sequenced the panned libraries and developed a clustering method that allows data to be aggregated within B-cell clonal families, improving signal-to-noise ratios and reducing the complexity of the repertoire.
We tested NanoMAP on three distinct pools of targets, collecting data on close to 1M unique nanobody sequences. We found that our specialized clustering method outperformed standard sequence clustering, producing clonal families that are coherent in sequence and function.
By aggregating sequencing data within clonal families, NanoMAP produced reliable and rich data on binding phenotypes for each antigen. Using this information, we discovered nanobodies recognizing functionally relevant, and evolutionarily conserved sites on each antigen, demonstrating the broad utility of our methods.
NIAID R01AI25704, NIGMS 5K12GM133314-07
Computational and Systems Immunology (COMP)
These findings highlight nanobodies as versatile platforms capable of overcoming key limitations of conventional therapies and facilitating clinical translation in precision oncology.
G. Romero-Hernández, Mario S. Valdés-Tresanco, Ernesto Moreno· Cell Biochemistry and Biophy...· 0 citations
Immuno-oncology is a rapidly growing field with an urgent need for well-characterized and highly specific research reagents, particularly in immune checkpoint targeting and acute myeloid leukemia (AML). We have developed recombinant monoclonal nanobodies (VHHs) targeting these critical areas to facilitate researc...
Annika V. Dalheim, S. Wendler, L. Yurlova et al.· Journal of Immunology· 0 citations
Background Conventional antibody discovery approaches that do not account for enrichment-driven biases, such as epitope immunogenicity, PCR amplification bias, or protein expression efficiency, may result in under-representation of rare yet functionally relevant clones, necessitating labor-intensive in vitro screening...
Tomoki Iemura, T. Kitawaki, R. Maeda et al.· Journal for ImmunoTherapy of...· 0 citations
The limit of quantification is improved to the fmol level in native biological environments, enabling the direct identification of neoantigens from as few as 5000 cells within 30 min, and the identification of a native Epstein–Barr virus-associated neoantigen is demonstrated.
Yan Gao, Yun-Ze Wu, Jie Jiang et al.· Journal of the American Chem...· 0 citations
Traditional in vitro screening of a nanobody library combined with an intracellular bioluminescence resonant energy transfer (BRET) proximity sensor approach for sequence down-selection can yield strong in vitro binders that also perform well as intrabodies, in this case capable of binding to and inhibiting the enzymat...
J. Wang, Victor L. Lam, E. Dunn et al.· bioRxiv· 0 citations
The successful adaptation of linking B cell receptor to antigen specificity through sequencing (LIBRA-seq) to immunized alpacas for the rapid identification of antigen-specific nanobodies, derived from heavy-chain antibodies, is demonstrated.
Sabina E. W. Leonard, Perry T. Wasdin, Katherine Webb et al.· Cell Reports Methods· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.